Bretillien Institute of Cancer and Radiotherapy

What Bretillien Institute of Cancer and Radiotherapy does

ICRB (Institut de Cancérologie et Radiothérapie Bretillien) is a private French oncology and radiotherapy establishment headquartered in Saint-Grégoire (Rennes), operating across two active treatment sites in Saint-Grégoire and Saint-Malo, with a third site under construction at Cesson-Sévigné for 2026 opening and an advanced consultation presence at Dinan. The institute provides comprehensive cancer care — radiotherapy and stereotactic radiotherapy, brachytherapy, chemotherapy, immunotherapy, targeted therapy, hormonotherapy, inpatient hospitalization, and supportive oncology care (Soins de Support) — alongside a clinical research program with approximately 500 active patients and 100 annual inclusions. Treatment planning is conducted through Réunions de Concertation Pluridisciplinaire (RCP), producing a Plan Personnalisé de Soins (PPS) for each patient. The organization employs 130 professionals, including 21 physicians, 35 radiology technicians, 17 medical physics experts, and 32 medical secretaries/assistants.

The technological backbone centers on three latest-generation EVO particle accelerators coupled with the ExacTrac Dynamic® imaging system, making ICRB the first French establishment to deploy this combination (June 2025). Additional capabilities include Hexapod treatment tables with 6 degrees of freedom, DIBH (Deep Inspiration Breath Hold) respiratory gating for cardiac protection during breast cancer radiotherapy, and surface laser tracking. These enable shortened stereotactic protocols — for example, five sessions for certain prostate cancers versus 20-39 previously. The institute reports 96% patient satisfaction (survey September–October 2025) and states equipment capacity sufficient to treat all cancer patients in the Ille-et-Vilaine territory until 2040.

The business model operates entirely within the French public healthcare reimbursement framework: all physicians are conventioned Secteur 1 with no fee overruns, and the institute accepts ALD, tiers-payant, CMU, and AME coverage. Revenue is generated from per-act reimbursement under Sécurité Sociale tariffs rather than commercial contracts. Distribution is delivered through ICRB's own facilities, with a 1,300m² Saint-Malo site (three treatment rooms) and the Saint-Grégoire host site at Les Hôpitaux Privés Rennais (LHPR). Strategic partnerships anchor the model: LHPR for Saint-Grégoire and the future Cesson-Sévigné site, Clinique de la Côte d'Emeraude for Saint-Malo, CHU de Rennes for emergency transfers, and technology integrations with Gustave Roussy (Résilience Care telemonitoring) and Omnidoc (tele-expertise). The institute holds ARS Bretagne 'Établissement de santé' recognition since January 2023 and completed its first HAS certification visit in April 2026. Governance is physician-led and self-financed, with no disclosed parent company, external investor, or private equity ownership.

Name

Bretillien Institute of Cancer and Radiotherapy

Legal name

Centre d'Oncologie Saint Vincent

Website

https://icrb.fr

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

51–100 employees

Short description

ICRB is a private French cancer treatment and research center providing radiotherapy, chemotherapy, immunotherapy, and supportive oncology care across multi-site facilities in Ille-et-Vilaine, serving regional cancer patients under the French public healthcare reimbursement system.

Ownership category

akta.pro rank

Product category

Oncology and Radiotherapy Services

NAICS

Ambulatory Health Care Services (621), Offices of Physicians (62111)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro industry

PRIMARYHLAFABAI

Ambulatory Oncology Centers (Outpatient Chemo/Radiation)

Healthcare & Life Sciences/Healthcare Providers & Systems/Ambulatory & Outpatient Care Centers

SECONDARYHLAFAHAC

Oncology & Cancer Specialty Hospitals

Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

SECONDARYHLAIAGAI

Nuclear Medicine Clinical Services & Therapy Centers

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

• Cancer treatment services
• Radiotherapy services
• Oncology care
• Brachytherapy treatment
• Supportive oncology care

Headquarters

HQ city

Saint-grégoire

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Healthcare Services Revenue: Revenue generated from oncology and radiotherapy treatment services provided to cancer patients. All practitioners are Conventionné Secteur 1 with no fee overruns, accepting ALD (long-term illness), tiers-payant (third-party payment), CMU and AME coverage.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ICRB is a private French healthcare establishment specialized in comprehensive cancer treatment and radiotherapy, providing radiotherapy (including stereotactic and brachytherapy), chemotherapy, immunotherapy, targeted therapy, hormone therapy, hospitalization, supportive care, and clinical research. It operates across three main sites in Brittany (Saint-Grégoire, Saint-Malo, and Cesson-Sévigné) using latest-generation EVO particle accelerators and ExacTrac Dynamic® imaging for precision treatment. All physicians are conventioned Secteur 1 with no fee overruns, accepting ALD, CMU, and AME coverage under the French public health system.

Product overview

ICRB (Institut de Cancérologie et Radiothérapie Bretillien) is a specialized cancer care establishment offering a unified suite of oncology services. The core offering comprises radiotherapy and brachytherapy treatments, supplemented by chemotherapy, immunotherapy, targeted therapy, and hormonotherapy. A dedicated Supportive Care (Soins de Support) department provides comprehensive patient support services. The institute also conducts clinical research. Key technology includes EVO particle accelerators with ExacTrac Dynamic® imaging for precision stereotaxic radiotherapy, and DIBH respiratory gating for cardiac protection in breast cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Radiotherapy / Stereotactic Radiotherapy / Brachytherapy High-precision radiation treatment using latest-generation EVO particle accelerators coupled with ExacTrac Dynamic® imaging for real-time patient positioning and organ tracking. Enables stereotactic radiotherapy protocols with fewer sessions (e.g., 5 sessions for prostate cancer). For cancer patients requiring radiotherapy treatment.
• Chemotherapy / Immunotherapy / Targeted Therapy / Hormone Therapy Medical drug treatments including chemotherapy, immunotherapy, targeted therapy, and hormonotherapy for various cancer types. For cancer patients requiring systemic drug-based treatment.
• Hospitalization Inpatient care services for cancer patients requiring hospitalization during treatment. For cancer patients needing continuous medical supervision during therapy.
• Supportive Care (Soins Oncologiques de Support) Comprehensive supportive care services including pain management, nutritional support, psychological support, and rehabilitation provided to patients during and after cancer treatment. For cancer patients requiring holistic non-curative supportive interventions.
• Clinical Research Medical and clinical research activities with approximately 500 patients in active follow-up and 100 patient inclusions per year. For cancer patients eligible for clinical trials and the broader oncology research community.

Quantifiable outcome

• Treatment sessions reduced from 20-39 to 5 for certain prostate cancers using stereotactic radiotherapy
• +5 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Les Hôpitaux Privés Rennais (LHPR) - St-GrégoirecoreStrategic or Co-development PartnerHost site for ICRB's main treatment facility at St-Grégoire location. Provides infrastructure for radiotherapy and oncology services.
• Clinique de la Côte d'Emeraude - Saint-MalocoreStrategic or Co-development PartnerHost site for ICRB's Saint-Malo treatment facility. Provides oncology and radiotherapy services on over 1300m².
• HPR Cesson-SévignécoreStrategic or Co-development PartnerPartner for future Cesson-Sévigné site (opening 2026). ICRB physicians ensure care for HPR Cesson-Sévigné patients.
• CHU de RennescoreStrategic or Co-development PartnerPartnership for emergency patient transfers and healthcare coordination for specialized cancer care.
• Clinique du Pays de Rance - DinanminorChannel Partner/ Reseller/ DistributorAdvanced consultation site (consultations avancées) providing local oncology services for patient accessibility.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Broad incumbents

• Institut Curie: Large French cancer center combining a hospital and a research center in Paris/Saint-Cloud and Orsay. Broader incumbent to ICRB — operates at a national scale in radiotherapy, medical oncology, and research, but overlaps directly in core radiotherapy and oncology services.
• GenesisCare: International private oncology and radiotherapy network with European operations. Broad incumbent to ICRB as a larger-scale private radiotherapy provider, offering comparable stereotactic and advanced radiotherapy services across multiple geographies.
• Gustave Roussy: Largest French and European cancer center, located in Villejuif. Broad incumbent peer of ICRB that also operates as a technology/clinical partner (Résilience Care deployment). Comparable in radiotherapy and oncology services but at much larger national-referral scale.

Others

• Unicancer: Federation of the 18 French CLCC cancer centers (including several direct peers above). Ecosystem participant rather than direct competitor — ICRB is not a Unicancer member but operates within the same French oncology network and competes for similar patient flows.
• Elsan: Leading French private hospital group hosting ICRB's main treatment sites (Hôpitaux Privés Rennais). Ecosystem participant — not a direct competitor but the host institution whose strategic decisions affect ICRB's physical operations and referral environment.

Direct peers

• Institut Paoli-Calmettes: CLCC cancer center in Marseille providing comprehensive oncology treatment including radiotherapy and innovative therapies. Directly comparable to ICRB as a Unicancer member offering specialized oncology, radiotherapy, and clinical research in a regional French catchment.
• Centre François Baclesse: Cancer center in Caen (Normandy) and member of the Unicancer network providing radiotherapy, chemotherapy, and supportive care. Comparable to ICRB as a French regional CLCC delivering multi-modality oncology care and active clinical research.
• Centre Oscar Lambret: CLCC cancer center in Lille (Hauts-de-France) treating all cancer types via radiotherapy, surgery, and medical oncology. Comparable to ICRB as a Unicancer French regional cancer center with multidisciplinary care and active research programs.
• Centre Léon Bérard: CLCC comprehensive cancer center in Lyon focused on oncology, radiotherapy, and clinical research. Comparable to ICRB as a Unicancer-affiliated French cancer treatment and research establishment with multidisciplinary radiotherapy and medical oncology services.
• Institut de Cancérologie de l'Ouest (ICO): Major French cancer center operating across western France (Angers, Nantes, Saint-Herblain). Directly comparable to ICRB as a multi-site regional oncology and radiotherapy establishment delivering comprehensive cancer care including radiotherapy, chemotherapy, and clinical research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institut-de-canc%C3%A9rologie-et-radioth%C3%A9rapie-br%C3%A9tillien

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bretillien Institute of Cancer and Radiotherapy